Format

Send to

Choose Destination
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):105-109. doi: 10.1182/hematology.2019000020.

Monitoring and treatment of MDS in genetically susceptible persons.

Author information

1
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Abstract

Genetic susceptibility to myelodysplastic syndrome (MDS) occurs in children with inherited bone marrow failure syndromes, including Fanconi anemia, Shwachman Diamond syndrome, and dyskeratosis congenita. Available evidence (although not perfect) supports annual surveillance of the blood count and bone marrow in affected persons. Optimal treatment of MDS in these persons is most commonly transplantation. Careful consideration must be given to host susceptibility to DNA damage when selecting a transplant strategy, because significant dose reductions and avoidance of radiation are necessary. Transplantation before evolution to acute myeloid leukemia (AML) is optimal, because outcomes of AML are extremely poor. Children and adults can present with germline mutations in GATA2 and RUNX1, both of which are associated with a 30% to 40% chance of evolution to MDS. GATA2 deficiency may be associated with a clinically important degree of immune suppression, which can cause severe infections that can complicate transplant strategies. GATA2 and RUNX1 deficiency is not associated with host susceptibility to DNA damage, and therefore, conventional treatment strategies for MDS and AML can be used. RUNX1 deficiency has a highly variable phenotype, and MDS can occur in childhood and later in adulthood within the same families, making annual surveillance with marrow examination burdensome; however, such strategies should be discussed with affected persons, allowing an informed choice.

PMID:
31808891
PMCID:
PMC6913506
[Available on 2020-12-06]
DOI:
10.1182/hematology.2019000020

Conflict of interest statement

Conflict-of-interest disclosure: S.M.D. has served as a consultant to Novartis and received research support from Alexion Pharmaceuticals and Prolacta.

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center